-
EP3436070
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3436070
| EP3436070 - CHIMERIC ANTIGEN RECEPTORS TARGETING CANCER [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 17.12.2020 Database last updated on 02.11.2024 | |
| Former | Request for examination was made Status updated on 04.01.2019 | ||
| Former | The international publication has been made Status updated on 07.10.2017 | Most recent event Tooltip | 28.03.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states University of Southern California 1150 South Olive Street, Suite 2300 Los Angeles, CA 90015 / US | [2019/06] | Inventor(s) | 01 /
CHAUDHARY, Preet M. 4606 Arcola Avenue Toluca Lake, California 91602 / US | [2019/06] | Representative(s) | Page White Farrer Bedford House 21a John Street London WC1N 2BF / GB | [N/P] |
| Former [2019/06] | Daniels, Jeffrey Nicholas Page White & Farrer Bedford House John Street London WC1N 2BF / GB | Application number, filing date | 17776591.4 | 29.03.2017 | [2019/06] | WO2017US24843 | Priority number, date | US201662314864P | 29.03.2016 Original published format: US 201662314864 P | [2019/06] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2017172981 | Date: | 05.10.2017 | Language: | EN | [2017/40] | Type: | A2 Application without search report | No.: | EP3436070 | Date: | 06.02.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 05.10.2017 takes the place of the publication of the European patent application. | [2019/06] | Search report(s) | International search report - published on: | US | 09.11.2017 | (Supplementary) European search report - dispatched on: | EP | 30.10.2019 | Classification | IPC: | A61K39/395, C07K14/705, C07K14/725, C07K16/28 | [2019/06] | CPC: |
C07K16/2866 (EP,KR,US);
C12N15/86 (EP,KR,US);
A61K2239/28 (EP,US);
A61K2239/31 (EP,US);
A61K2239/38 (EP,US);
A61K2239/47 (EP,US);
A61K2239/48 (EP,US);
A61K2239/59 (EP,US);
A61K39/461 (EP,US);
A61K39/4611 (EP,KR,US);
A61K39/4631 (EP,KR,US);
A61K39/4632 (EP,US);
A61K39/4633 (EP,US);
A61K39/464402 (EP,US);
A61K39/464412 (EP,US);
A61K39/464413 (EP,US);
A61K39/464488 (EP,US);
A61K45/06 (US);
A61K48/005 (EP,KR,US);
A61P35/00 (EP,KR,US);
C07K14/5412 (KR);
C07K16/2803 (EP,KR,US);
C07K16/2896 (US);
C12N5/0636 (EP,US);
C12N5/0646 (EP,US);
A61K2121/00 (KR);
A61K2300/00 (KR);
C07K2317/31 (US);
C07K2317/622 (EP,KR,US);
C07K2319/02 (US);
C07K2319/03 (KR,US);
C07K2319/33 (EP,KR,US);
C12N2510/00 (KR);
C12N2740/16043 (EP,KR,US)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/06] | Title | German: | GEGEN KREBS GERICHTET CHIMÄRE ANTIGENREZEPTOREN | [2019/06] | English: | CHIMERIC ANTIGEN RECEPTORS TARGETING CANCER | [2019/06] | French: | RÉCEPTEURS ANTIGÉNIQUES CHIMÉRIQUES CIBLANT LE CANCER | [2019/06] | Entry into regional phase | 12.10.2018 | National basic fee paid | 12.10.2018 | Search fee paid | 12.10.2018 | Designation fee(s) paid | 12.10.2018 | Examination fee paid | Examination procedure | deleted | Date on which the examining division has become responsible | 12.10.2018 | Examination requested [2019/06] | 29.05.2020 | Amendment by applicant (claims and/or description) | 16.12.2020 | Despatch of a communication from the examining division (Time limit: M04) | 26.04.2021 | Reply to a communication from the examining division | 19.10.2022 | Despatch of a communication from the examining division (Time limit: M04) | 28.02.2023 | Reply to a communication from the examining division | Fees paid | Renewal fee | 27.03.2019 | Renewal fee patent year 03 | 27.03.2020 | Renewal fee patent year 04 | 29.03.2021 | Renewal fee patent year 05 | 28.03.2022 | Renewal fee patent year 06 | 27.03.2023 | Renewal fee patent year 07 | 27.03.2024 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [I]WO2014152177 (ANTHROGENESIS CORP [US]); | [A]WO2015150771 (UCL BUSINESS PLC [GB]); | [A]WO2016014535 (NOVARTIS AG [CH], et al); | International search | [A]US2006222588 (SANDBERG BENGT [SE], et al); | [Y]US2013017575 (GARCIA-MARTINEZ LEON [US], et al); | [Y]US2013143791 (PETZELBAUER PETER [AT], et al); | [A]US2014271635 (BROGDON JENNIFER [US], et al); | [Y]WO2015150526 (CELLECTIS [FR]); | [PY]WO2016210447 (UNIV SOUTHERN CALIFORNIA [US]); | [PY]WO2017103596 (CELLULAR THERAPEUTICS LTD [GB]); | by applicant | EP0239400 | US4708871 | EP0404097 | WO9109967 | EP0519596 | US5199942 | WO9311161 | US5225539 | WO9317105 | EP0592106 | US5350674 | US5399346 | US5530101 | US5565332 | US5580859 | US5585089 | US5585362 | US5589466 | US5641870 | US5766886 | US5858358 | US5883223 | WO0129058 | US6326193 | WO0196584 | US6342220 | US6352694 | US6407213 | US6534055 | US6692964 | US6797514 | US2005042664 | US2005048617 | US6867041 | US6887466 | US2005100543 | US6905680 | US6905681 | US6905874 | US2005175606 | EP1616881 | WO2006020258 | US2006121005 | US7067318 | US7112324 | WO2006121168 | US7144575 | US2007014794 | US7172869 | US7175843 | WO2007024715 | US7232566 | US2009082299 | WO2009101611 | WO2009114335 | US2011081311 | US7943743 | US8008449 | US2012039906 | US8124084 | US2012141413 | US2012177598 | US2012269814 | US8354509 | WO2013024097 | EP2568109 | WO2013059343 | US2014256706 | WO2015142675 | US19500623966 | WO2008US80373 | WO2012US60646 |